"MHTX invested millions of dollars to commercialize Edward Flynn’s work to create a reliable and inexpensive cancer diagnostic, with a stated goal to identify pre symptomatic cancers well before they metastasize in humans.“"
NEW YORK--Manhattan Scientifics Inc., a principal & major shareholder of Imagion Biosystems Ltd. (IBX.AX) announces IMAGION’S initiation of manufacturing medical devices and pharma products to be used in first human clinical studies of very early cancer detection as approved by the FDA.
The primary operational focus for Imagion’s past quarter has been on ensuring the readiness of its contract-manufacturing partners to begin the manufacturing of the nanoparticle formulation to be used in the study. Imagion is pleased to report it has purchased equipment and supplies and has completed the necessary vendor qualifications and audits to confirm compliance with GMP (Good Manufacturing Practice), required for the manufacturing of medical devices and pharmaceutical products used in human clinical studies.
Marvin Maslow, Chairman of MHTX said, “MHTX invested millions of dollars to commercialize Edward Flynn’s work to create a reliable and inexpensive cancer diagnostic, with a stated goal to identify pre symptomatic cancers well before they metastasize in humans.“
Manhattan Scientifics Inc. (www.mhtx.com) is focused on commercialization of disruptive technologies in the nano medicine space.
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.